These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 36799932)

  • 21. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiologic, Immunologic, and Virus Characteristics in Patients With Paired Severe Acute Respiratory Syndrome Coronavirus 2 Serology and Reverse-Transcription Polymerase Chain Reaction Testing.
    Shragai T; Smith-Jeffcoat SE; Koh M; Schechter MC; Rebolledo PA; Kasinathan V; Wang Y; Hoffman A; Miller H; Tejada-Strop A; Jain S; Tamin A; Harcourt JL; Thornburg NJ; Wong P; Medrzycki M; Folster JM; Semenova V; Steward-Clark E; Drobenuic J; Biedron C; Stewart RJ; da Silva J; Kirking HL; Tate JE;
    J Infect Dis; 2022 Jan; 225(2):229-237. PubMed ID: 34216468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals.
    Fraley E; LeMaster C; Geanes E; Banerjee D; Khanal S; Grundberg E; Selvarangan R; Bradley T
    BMC Med; 2021 Jul; 19(1):169. PubMed ID: 34304742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
    Scaggs Huang F
    J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
    Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
    mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.
    McAndrews KM; Dowlatshahi DP; Dai J; Becker LM; Hensel J; Snowden LM; Leveille JM; Brunner MR; Holden KW; Hopkins NS; Harris AM; Kumpati J; Whitt MA; Lee JJ; Ostrosky-Zeichner LL; Papanna R; LeBleu VS; Allison JP; Kalluri R
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32796155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections.
    Huber T; Steininger P; Irrgang P; Korn K; Tenbusch M; Diesch K; Achenbach S; Kremer AE; Werblow M; Vetter M; Bogdan C; Held J
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1983-1997. PubMed ID: 34109500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 Seroconversion in Response to Infection and Vaccination: a Time Series Local Study in Brazil.
    Huergo LF; Paula NM; Gonçalves ACA; Kluge CHS; Marins PHSA; Camargo HSC; Sant'Ana TP; Farias LRP; Aldrighi JD; Lima ÊS; Jacotenski GT; Vargas LR; Costa G; Weissheimer KV; Nazário MG; Teixeira KN; Conzentino MS
    Microbiol Spectr; 2022 Aug; 10(4):e0102622. PubMed ID: 35770982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of IgM, IgG, IgA and neutralizing antibody responses to SARS-CoV-2 infection and mRNA vaccination.
    Fleischmann CJ; Bulman CA; Yun C; Lynch KL; Wu AHB; Whitman JD
    J Med Microbiol; 2023 Jan; 72(1):. PubMed ID: 36748419
    [No Abstract]   [Full Text] [Related]  

  • 30. Validation of laboratory developed serology assays for detection of IgG antibody to severe acute respiratory syndrome coronavirus 2 in the South African population.
    Matefo L; Cloete VV; Armand BP; Dominique G; Samantha P; John F; Craig T; Daniel W; Theresa L; Sunetra G; Maréza B; Danelle VJ; Jane BF
    J Virol Methods; 2022 Sep; 307():114571. PubMed ID: 35750222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors associated with anti-SARS-CoV-2 spike antibody titers after a second BNT162b2 mRNA COVID-19 vaccination in Japanese hemodialysis patients.
    Hirai K; Shimotashiro M; Sonoda T; Okumura T; Ookawara S; Morishita Y
    Clin Exp Nephrol; 2022 Sep; 26(9):925-932. PubMed ID: 35426594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cohort Profile:The Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 vaccines (ENFORCE).
    Stærke NB; Reekie J; Johansen IS; Nielsen H; Benfield T; Wiese L; Søgaard OS; Tolstrup M; Iversen KK; Tarp B; Larsen FD; Larsen L; Lindvig SO; Holden IK; Iversen MB; Knudsen LS; Fogh K; Jakobsen ML; Traytel AK; Ostergaard L; Lundgren J;
    BMJ Open; 2022 Dec; 12(12):e069065. PubMed ID: 36585137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.
    Havervall S; Ng H; Jernbom Falk A; Greilert-Norin N; Månberg A; Marking U; Laurén I; Gabrielsson L; Salomonsson AC; Aguilera K; Kihlgren M; Månsson M; Rosell A; Hellström C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Lord M; Åberg M; Hedhammar M; Tegel H; Dönnes P; Phillipson M; Nilsson P; Klingström J; Mangsbo S; Hober S; Thålin C
    J Intern Med; 2022 Jan; 291(1):72-80. PubMed ID: 34459525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection.
    Schuh AJ; Satheshkumar PS; Dietz S; Bull-Otterson L; Charles M; Edens C; Jones JM; Bajema KL; Clarke KEN; McDonald LC; Patel S; Cuffe K; Thornburg NJ; Schiffer J; Chun K; Bastidas M; Fernando M; Petropoulos CJ; Wrin T; Cai S; Adcock D; Sesok-Pizzini D; Letovsky S; Fry AM; Hall AJ; Gundlapalli AV
    Microbiol Spectr; 2022 Aug; 10(4):e0124722. PubMed ID: 35856710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study.
    Letizia AG; Ge Y; Vangeti S; Goforth C; Weir DL; Kuzmina NA; Balinsky CA; Chen HW; Ewing D; Soares-Schanoski A; George MC; Graham WD; Jones F; Bharaj P; Lizewski RA; Lizewski SE; Marayag J; Marjanovic N; Miller CM; Mofsowitz S; Nair VD; Nunez E; Parent DM; Porter CK; Santa Ana E; Schilling M; Stadlbauer D; Sugiharto VA; Termini M; Sun P; Tracy RP; Krammer F; Bukreyev A; Ramos I; Sealfon SC
    Lancet Respir Med; 2021 Jul; 9(7):712-720. PubMed ID: 33865504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved diagnosis of SARS-CoV-2 by using nucleoprotein and spike protein fragment 2 in quantitative dual ELISA tests.
    De Marco Verissimo C; O'Brien C; López Corrales J; Dorey A; Cwiklinski K; Lalor R; Doyle JM; Field S; Masterson C; Ribes Martinez E; Hughes G; Bergin C; Walshe K; McNicholas B; Laffey JG; Dalton JP; Kerr C; Doyle S
    Epidemiol Infect; 2021 Jun; 149():e140. PubMed ID: 34099081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV.
    Tuan JJ; Zapata H; Critch-Gilfillan T; Ryall L; Turcotte B; Mutic S; Andrews L; Roh ME; Friedland G; Barakat L; Ogbuagu O
    HIV Med; 2022 Feb; 23(2):178-185. PubMed ID: 34632695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine.
    Kobashi Y; Shimazu Y; Kawamura T; Nishikawa Y; Omata F; Kaneko Y; Kodama T; Tsubokura M
    PLoS One; 2022; 17(6):e0269917. PubMed ID: 35687563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.